https://www.live-feeds.com/feed/a-new-use-for-glp-1s-amylyx-pharma-catapults-to-3-year-highContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/a-new-use-for-glp-1s-amylyx-pharma-catapults-to-3-year-highhttps://www.live-feeds.com/feed/a-new-use-for-glp-1s-amylyx-pharma-catapults-to-3-year-high#u45250Wed, 19 Aug 2026 17:45:32 +0000Amylyx Pharmaceuticals' stock surged to a 3-year high after its GLP-1 blocker, avexitide, met primary endpoints in a Phase 3 trial, reducing low blood sugar episodes in bariatric surgery patients. The trial, called LUCIDITY, evaluated the safety and efficacy of avexitide. Amylyx's stock rose 55% following the announcement. The company's GLP-1 antagonist is being explored for a new use beyond its initial focus on ALS.Why it mattersThe trial success marks a significant milestone for Amylyx Pharmaceuticals, which has been exploring new applications for its GLP-1 antagonist. GLP-1 r